Phase I dose escalation and expansion study to evaluate SAR intravenous administration as single agent...One hundred and fourteen patients (Pts) with heavily pretreated solid tumors expressing CA6 in ≥ 30% tumor cells with an intensity 2/3+ by immunohistochemistry were enrolled….Tumor regression was noted in about 60% Pts at 190 and 90 mg/m² D1,D8 and 35% Pts at 150 and 120 mg/m² q2w. One complete response (ovary), 8 partial responses (3 breast, 2 ovary, 1 NSCLC, 1 cervix and 1 bladder) and 39% stable disease were noted. Highest overall response rate (ORR) was observed in 2/15 at 90 mg/m² D1,D8 and 3/23 at 190 mg/m²....SAR 90 mg/m² D1,D8 q3w provided a favorable safety profile and encouraging antitumor activity...